Prot #BP39365: An Open-Label, Multi-Center, Randomized, Dose-Escalation, Phase IB Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281, in Combination with Atezolizumab ± Bevacizumab, Following Obinutuzumab Pre-Treatment, in Pa

Project: Research project

Project Details

StatusActive
Effective start/end date8/11/178/11/20

Funding

  • INC Research, LLC (Prot #BP39365)
  • Roche TCRC, Inc. (Prot #BP39365)